To evaluate the safety and efficacy of particle therapy (PT) using pencil beam scanning (PBS) technique for early stage non-small cell lung cancer (NSCLC). From 08/2014 to 03/2018, 31 consecutive patients with sum of the longest diameters of primary tumor and hilar lymph node < 5 cm, N0–1, M0 NSCLC treated with PT were retrospectively analyzed. Gating/active breathing control techniques were used to control tumor motion in 20 and 7 patients. PBS-based proton radiotherapy (PRT) or carbon ion radiotherapy (CIRT) plans were designed via Syngo® planning system. PRT, PRT + CIRT boost, and CIRT were used in 6, 6 and 19 patients, respectively. Prescriptions were categorized to 3 levels: 5–7.5 GyE * 8–10 Fx, 4–5 GyE * 15–16 Fx and 2.25–3.5 GyE * 20–31 Fx. Thirty-one patients (20 males and 11 females) with a median age of 71 (50–80) years were enrolled with a median follow-up time of 12.1 (2.9–45.2) months. Fourteen were adenocarcinomas, 7 squamous cell carcinomas, 4 non-specified NSCLC and 6 had no histological diagnosis (4/6 had previous resected lung cancer). The median tumor size was 3.1 (1.1–4.7) cm. No grade 4–5 toxicities were observed. One patient experienced grade 3 (per the Common Terminology Criteria for Adverse Events version 4.03) radiation-induced lung injury (RILI) at 6.7 months from radiation started. Grade 2 acute toxicities included hematological toxicities (5 cases), RILI (2), plural pain (1) and dermatitis (1). Grade 2 late toxicities included RILI (3) and asymptomatic rib fracture (1). Three patients had progressed disease at 4.0~10.6 months after the initiation of PT. One experienced local failure with simultaneous distant failure and died of brain metastasis at 10.8 months; one developed regional and distant failure and died of lung infection at 8.7 months; the other experienced isolated distant failure only and his disease was well controlled after salvage systemic therapy. The estimated rates of progression-free survival, local control, cause-specific survival and overall survival at 1, 2 years were 85.5% and 85.5%, 95.2% and 95.2%, 95.0% and 95.0%, 90.7% and 90.7%, respectively. PBS-based PT appears safe and effective for early stage NSCLC. Further follow-up and investigation is warranted. ISRCTN, ISRCTN78973763. Registered 14 August 2018- Retrospectively registered, http://www.isrctn.com/ISRCTN78973763 .
Purpose The study aimed to assess the impact of carbon-ion radiotherapy (CIRT) on intratumoral hypoxia in patients with locally advanced non-small cell lung cancer (LA-NSCLC) and the predictive value of 18F-fluoromisonidazole (FMISO) and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Methods We retrospectively analyzed patients with stage IIB–IIIC NSCLC treated with CIRT who underwent baseline 18F-FMISO and 18F-FDG PET/CT and post-CIRT 18F-FMISO PET/CT. Regions of interest (ROIs) with a diameter ≥ 3 cm were analyzed. An ROI was defined as hypoxia with a tumor-to-muscle ratio (TMR) ≥ 1.4 on 18F-FMISO PET/CT. Survival outcomes were evaluated using Kaplan-Meier curves, and group comparisons were performed using Log-rank test. Results Thirty-seven eligible patients with 42 ROIs were included. Significant reductions in all 18F-FMISO parameters were observed after CIRT. ROIs with or without pre-CIRT hypoxia achieved similar local control (LC, with vs. without hypoxia: 75.5% vs. 85.5%, p = 0.799). The overlap ratios of hypoxic volumes between pre-/post-CIRT were 58.13%–81.34%. The combination of 18F-FDG uptake and post-CIRT hypoxia status demonstrated the strongest predictive value for LC (high vs. low uptake: 46.8% vs. 95.8%, p = 0.0004) with the highest area under the receiver operating characteristic curve (0.783, p = 0.01) among all evaluated combinations. Conclusion Tumor hypoxia detected by 18F-FMISO PET/CT was significantly decreased after CIRT in patients with LA-NSCLC. Similar LC was achieved in patients with or without pre-CIRT hypoxia, while post-CIRT hypoxia clearance resulted in a non-significant trend toward improved LC. Combining 18F-FMISO and 18F-FDG PET/CT might provide enhanced prognostic value. Further investigation is warranted to explore individualized CIRT dose painting strategies guided by multi-tracer PET/CT imaging.